Insulet (PODD) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Insulet

NasdaqGS•Healthcare•Medical Devices

$141.55+0.95(0.01%)Pre-market

Market Cap

$9.81B

P/E

26.1x

P/S

3.2x

P/B

6.9x

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

How this company scores

GoodMetricSide Score: 79/100

Strongest: Profitability (25/25); weakest: Cash & Earnings Quality (14/25).

Profitability25/25

Growth25/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality14/25

Strengths

Growing revenueStrong marginsHigh ROERising earnings

No red flags in the last 8 quarters.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 26.1x5y range 26.1x – 36749.1x

Currently below its 19-quarter median.

P/S · 3.2x5y range 3.2x – 20.6x

Currently below its 20-quarter median.

P/B · 6.9x5y range 6.9x – 43.9x

Currently below its 20-quarter median.

Price & Volume

Market Cap $9.81B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $3.05B
Q. Revenue: $801.70M
TTM EBITDA: $615.00M
TTM Op. Income: $515.70M
Q. Op. Income: $129.70M
TTM Net Income: $375.30M
Q. Net Income: $95.00M
EPS: $1.37
Shares Out.: $69.30M

$3.05B in TTM revenue grew 29.4% YoY, reaching $801.70M last quarter. TTM EBITDA of $615.00M and TTM operating income of $515.70M show growth is flowing through to the bottom line. TTM net income of $375.30M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 6 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 70.2%
EBITDA Margin: 19.5%
Op. Margin: 16.2%
Net Margin: 11.8%

Op. margin of 16.2% is down 2.5% YoY — costs are rising relative to revenue. Net margin at 11.8% and gross margin of 70.2% show how much of each revenue dollar survives to profit. Over the past year, operating margin is down 13% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 26.1x
P/S Ratio: 3.2x
P/B Ratio: 6.9x

At 26.1x P/E, the stock trades within typical market levels. P/S of 3.2x and P/B of 6.9x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Across the last 8 quarters, P/E has fallen for 4 consecutive quarters — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $3.17B
Cash: $534.90M
Long-Term Debt: $929.50M
Book Value: $1.42B
D/E Ratio: 0.7
Debt/EBITDA: 5.9

With $3.17B in assets and $929.50M in long-term debt, D/E is 0.7and book value is $1.42B — a conservative capital structure with a cushion to weather downturns. Over the past year, debt/equity is up 2% — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $88.40M
TTM Free Cash Flow: $293.70M
FCF Margin: 9.6%
FCF / Net Income: 0.8

TTM FCF of $293.70M on $88.40M in operating cash flow. The FCF / Net Income ratio of 0.8x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is down 26% — a weakening trend.